Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease
AssigneeClinical Homecare, Corp.
InventorMichael Rothkopf
Life of this patent
Estimating the term…
Abstract
Methods of treating malnutrition associated with chronic lung diseases comprising the administration of metabolically active peptides in an amount sufficient to increase circulating somatomedin C levels more than 0.8 U/ml plasma above the patient's baseline SmC level, along with nutritional supplementation providing a daily caloric intake of between 100% and 200% of the patient's baseline resting energy expenditure; and formulations utilized therein.
Claims14
A method for treating malnutrition in a patient having a chronic lung disease, comprising concurrently administering to a patient having a chronic lung disease, recombinant human growth hormone in an amount sufficient to increase circulating somatomedin C levels from 0.8 to 3.5 U/ml plasma above the patient's baseline plasma somatomedin C level, and total parenteral nutrition (TPN) comprising the following nutrients, in percentages of total caloric intake:
- ______________________________________ Proteins 10 to 30% Carbohydrates 10 to 60% Fats 30 to 70% ______________________________________
- said TPN being administered in an amount providing a daily caloric intake in the range from 100 to 200% of the patient's resting energy expenditure.
A method for treating malnutrition in a patient having a chronic lung disease, which comprises concurrently administering to the patient;
- a) human growth hormone in an amount sufficient to increase circulating somatomedin C levels from 0.8 to 3.5 U/ml plasma above the patient's baseline plasma somatomedin C level;
- and
- b) a nutritional supplement, in an amount providing a daily caloric intake in the range of from 100 to 200% of the patient's resting energy expenditure (REE), said supplement providing less than 300 g of carbohydrate per day.
A nutrient formulation for a patient having a baseline circulating somatomedin level less than 1.0 U/ml plasma, which comprises in combination:
- (a) a human growth hormone in an amount which is sufficient to increase the patient's baseline circulating somatomedin C levels by from 1.0 to 3.5 U/ml plasma;
- and
- (b) a nutritional supplement in an amount providing a daily caloric intake from 100 to 200% of the patient's baseline resting energy expenditure, said nutritional supplement providing carbohydrates in an amount of 10 to 60% of total caloric content.
Dependencies are inferred from the claim text.